Dr Jeffery Huang Zhifeng, Associate Professor in the Department of Physics at HKBU, has designed the helical metal nanostructures to mediate the manipulation of the chirality of drug molecules.
Scientists from Hong Kong Baptist University (HKBU) have developed a novel technique that can produce pure therapeutic drugs without the associated side effects.
The approach, which uses a nanostructure fabrication device, can manipulate the chirality of drug molecules by controlling the direction a substrate is rotated within the device, thus eliminating the possible side effects that can arise when people take drugs containing molecules with the incorrect chirality.
Published in the renowned international scientific journal Nature Chemistry, the research findings pave the way towards the mass production of purer, cheaper and safer drugs that can be made in a scalable and more environmentally-friendly way.
Control of molecular chirality improves drug safety
Many chemical molecules have two configurations, or chiral versions, that are mirror images of each other. While sharing the same molecular formula, the two chiral versions have different arrangements of their constituent atoms in space. The two versions of the molecules are characterised by left-handed and right-handed chiral configurations like human hands. Molecules with “left-handed” and “right-handed” chirality can have totally different biochemical effects.
More than half of the therapeutic drugs are made up of equal amounts of left-handed and right-handed chiral molecules, commonly known as “racemates”; one can cure specific diseases, but the other may have adverse effects. Separating and producing molecules with only the chiral arrangement (known as a single enantiomer) responsible for the therapeutic effects can help to produce drugs with improved safety and efficacy.
Macro-scale control of molecular chirality
In general, molecules have an extremely small size ranging from one-millionth to one hundred-thousandth of the diameter of a human hair. It is therefore extremely challenging to selectively produce one of the two chiral molecule versions using “macro-scale” control (i.e. the dimensional scale that can be seen using the naked eye and operated by hand). To produce single-enantiomer drugs, chemists have overwhelmingly used molecules called “chiral ligands” to effectively control the molecular chirality of drugs in the laboratory or industry at the molecular scale, a process called asymmetric synthesis. However, the existing technologies for producing single-enantiomer drugs are composed of complicated procedures, which are expensive and environmentally-unfriendly.
Dr Jeffery Huang Zhifeng, Associate Professor in the Department of Physics at HKBU, and his research team devised a novel approach to manipulating molecular chirality through macro-scale control in collaboration with Sichuan University, Guangxi Medical University and the Southern University of Science and Technology. It involves mediating the manipulation with helical metal nanostructures (i.e. metal nanohelices) that are in the shape of a helical spring, and they have a characteristic size of one-thousandth of the diameter of a human hair.
Direction of rotation determines molecular chirality
The research team fabricated the metal nanohelices using a nanofabrication technique called glancing angle deposition (GLAD). Silver and copper were deposited onto a supporting substrate that was rotated clockwise and counterclockwise to fabricate the right-handed and left-handed metal nanohelices, respectively.
The research team then used ultraviolet light to induce a chemical reaction. This caused 2-anthracenecarboxylic acid (AC) molecules adsorbing on the metal nanohelices to undergo the chemical reaction and form chiral molecular products, which are similar to some chiral drugs. When AC was attached to the surface of the right-handed metal nanohelices and exposed to ultraviolet light, it preferentially produced “right-handed” chiral molecular products. By the same token, when AC was adsorbed on the surface of the left-handed metal nanohelices and exposed to ultraviolet light, it preferentially produced “left-handed” chiral molecular products. In other words, the chirality of the molecular product can be reliably determined by the chirality of the metal nanohelices, which is controlled by the direction of substrate rotation.
The research demonstrates that controlling the direction of substrate rotation at a macroscopic level can conveniently manipulate molecular chirality. This is an unprecedented application of the macro-scale method (through the control of the rotation direction of a 4-inch substrate holder) to manipulate chirality at the molecular-scale (chiral molecular products in the range of one-billionth of a metre).
Green approach to reducing drug side effects
“Our success in manipulating molecular chirality through macroscopic engineering allows the convenient synthesis of drugs in single-enantiomer forms with only left- or right-handedness. Hence, it will help get rid of the adverse, sometimes fatal, side effects of many therapeutic drugs,” said Dr Huang.
The use of chiral ligands in the conventional method of asymmetric synthesis is inevitable, and it may cause pollution to enter the environment. In contrast, in this novel approach the metal nanohelices can be used repeatedly to produce single-enantiomer drugs without the use of chiral ligands. As a result, it paves the way towards the mass production of affordable therapeutic drugs that are made in a scalable manner with recyclable materials.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Pure therapeutic drug production
- MediPharm Labs Reports First Quarter 2020 Results, Clears Path for International Growthon June 18, 2020 at 10:07 pm
The Company also provided an update on the build out of its global Good Manufacturing Practices (“GMP”) certified production platforms and new international medicinal, wellness and adult ...
- Willow Biosciences Announces Expedited Pilot Production and Adds Multiple New Cannabinoids to Portfolioon June 17, 2020 at 5:00 am
PRNewswire/ - Willow Biosciences Inc. (“Willow” or the “Company”) (TSX: WLLW) (OTCQB: CANSF) is pleased to announce that it has further accelerated its path to commercialization following continued ...
- Fauci Foresees “More Than 1 Winner” in Race for COVID-19 Vaccines, Drugson June 10, 2020 at 5:14 am
To ameliorate a pandemic that infectious disease expert Anthony Fauci calls his “worst nightmare,” a winner-takes-all solution won’t be enough. Fauci, who ...
- Auburn firm lands $143 million contract for COVID-19 vaccine packageson June 9, 2020 at 10:16 am
When researchers perfect a vaccine to combat coronavirus, an Auburn company will produce its packaging. SiO2 Materials Science, located in Auburn Technology Park West, has landed a $143 million ...
- NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac ® in Lung Canceron June 9, 2020 at 3:04 am
The trial follows FDA allowance of an investigational new drug ... Particle Therapeutic Platform The NanOlogy submicron particle therapeutic platform is based on a proprietary production ...
Go deeper with Google Headlines on:
Pure therapeutic drug production
Go deeper with Bing News on:
- Somerset Drug Ring Busted, $47K In Marijuana Seized: Prosecutoron June 23, 2020 at 11:59 am
Four South Bound Brook residents and one from Annadale were charged in connection with running a drug facility, authorities said.
- The high cost of prescription drugs: causes and solutionson June 23, 2020 at 11:34 am
In the case of biologic drugs, cumbersome manufacturing and biosimilar approval processes are additional barriers that greatly limit the number of competitors that can enter the market. High ...
- Perry County drug trafficker sentencedon June 23, 2020 at 11:32 am
Perry County drug trafficker sentenced William Layne plead guilty to drug trafficking and manufacturing and was sentenced to a total of 8 to12 years in prison last week. Check out this story on ...
- The Latest: US drug agency head vows vaccine independenceon June 23, 2020 at 11:09 am
The head of the U.S. Food and Drug Administration says his agency is maintaining an arm’s-length relationship with a White House-led effort to quickly produce a COVID-19 vaccine once it’s approved.
- Sanofi Moves Up Target For Its COVID-19 Vaccine; Gilead Doubles Estimate Of Remdesivir Productionon June 23, 2020 at 10:48 am
French drugmaker Sanofi SA (SASY.PA) said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain’s GlaxoSmithKline Plc (GSK.L) by the first half of next ...